Tamoxifen
Indication: Hormone receptor-positive breast cancer adjuvant therapy
Population PK simulator for tamoxifen, an oral selective estrogen receptor modulator whose active metabolite endoxifen is formed via CYP2D6. Models parent-metabolite exposure, CYP2D6 phenotype/genotype, inhibitor effects, age, and body weight to support breast cancer dose adaptation.
Drug Overview
Clinical Context
- Molecular Target
- Estrogen receptor modulation and endoxifen exposure
- Drug Class
- Selective estrogen receptor modulator
- Therapeutic Area
- Oncology
- Indication
- Hormone receptor-positive breast cancer adjuvant therapy
- Route of Administration
- Oral
Model Information
- Model Type
- Parent-metabolite population PK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Tamoxifen allows you to explore concentration-time profiles under different dosing scenarios. The underlying Parent-metabolite population PK model characterizes the pharmacokinetics of this selective estrogen receptor modulator following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Tamoxifen PK simulator?
This is a free, interactive pharmacokinetic simulator for Tamoxifen used in Hormone receptor-positive breast cancer adjuvant therapy. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Tamoxifen belong to?
Tamoxifen is classified as a Selective estrogen receptor modulator that targets Estrogen receptor modulation and endoxifen exposure. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Tamoxifen. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Parent-metabolite population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
G-CSF Effects in Carboplatin-Treated Cancer Patients
Chemotherapy-induced neutropenia
Methotrexate population PK in Mexican pediatric ALL
Acute lymphoblastic leukemia in pediatric patients receiving high-dose methotrexate
Population PKPD
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses
Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
Ready to Simulate?
Launch the Tamoxifen simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community